Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
LUX-Breast 1 Infographic thumb
 
Rating:00
view image larger
Related links:
outlook_for_personalised_medicine_Kathleen_Pritchard_thumb
Could new cancer targets change the outlook for personalised medicine?
Interview with Kathleen Pritchard, MD, FRCPC Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
Read more >
Pivotal_study_on_afatinib_thumb
Pivotal study on afatinib
Pivotal study on afatinib may challenge standard first line treatment
Read more >

LUX-Breast 1 Infographic

01.12.2011

A Phase III open-label, randomised trial to assess the efficacy of afatinib* plus vinorelbine versus trastuzumab plus vinorelbine in ErbB2 (HER2)-positive metastatic breast cancer patients after prior treatment with trastuzumab.
Inclusion Criteria
  • Female patients aged 18 years or older
  • Patients with stage IV, confirmed ErbB2 (HER2)-positive metastatic breast cancer
  • (Archived) tumour tissue sample available for central re-assessment of ErbB2 (HER2)-status
  • Progression after one prior treatment of trastuzumab (either adjuvant or first-line)
  • Anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer ECOG score of 0 or 1
  • At least one measurable lesion according to RECIST 1.1

If you are an investigator interested in becoming involved in the study and have potentially eligible patients, please contact Boehringer Ingelheim at: clintriage.rdg@boehringer-ingelheim.com or visit ClinicalTrials.gov for more information about LUX-Breast 1

*Afatinib is an investigational compound. Its safety and efficacy have not yet been fully established.
VIEW PREVIEW ADD TO SELECTION DOWNLOAD